NT_1170x120_1-11-18

Jardiance

Study to probe Jardiance effects on kidney disease

Study to probe Jardiance effects on kidney disease

RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Co.  yesterday announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical

Jardiance approved to cut cardiovascular death risk

Jardiance approved to cut cardiovascular death risk

RIDGEFIELD, Conn., and INDIANAPOLIS — Jardiance tablets, marketed by Boehringer Ingelheim and Eli Lilly and Co., have been approved by the Food and Drug Administration to cut the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. BI and Lilly said the FDA clearance makes Jardiance (empagliflozin) the first type